ESMO - European Society for Medical Oncology

Several studies presented at #ESMO25 describe tissue-agnostic biomarker approaches utilising the latest technology for better patient selection and outcomes with #immunotherapy. A composite biomarker, including tumour mutational burden and tumour infiltrating lymphocyte score, was associated with response to neoadjuvant immunotherapy, while specific molecular alterations responsible for microsatellite instability (#MSI) may provide further predictive value in guiding immunotherapy in patients with MSI/deficient mismatch repair tumours. #ArtificialIntelligence (AI)-driven computational pathology, a technique involving the use of #AI to detect cells with similar histological features, may have utility in predicting the likelihood of tumour progression linked to specific genetic alterations. Read the full commentary in the #ESMODailyReporter 👉https://ow.ly/IoNs50XeYFU #ImmunoOncology #TranslationalResearch

#ESMO25: Treatment optimisation to minimise harm without compromising efficacy is a clinical imperative. Personalising #CancerTreatment is not just about developing novel drugs, but also about refining how we use existing ones. Elena Castro explains how existing therapies and regimens may be refined using technological advances, such as next-generation sequencing (#NGS), big data analysis and #ArtificialIntelligence (#AI) tools, to challenge current paradigms of care. Read her Editorial in the #ESMODailyReporter➡️ https://ow.ly/5wzP50XeZSx #CancerCare #HealthcareInnovation #oncology

#ESMO25: The phase III FORTITUDE-101 #ClinicalTrial met its primary endpoint, reporting significantly improved short-term survival with the first-in-class FGFR2b inhibitor bemarituzumab added to chemotherapy as first-line therapy in FGFR2b-overexpressing, unresectable or metastatic #Gastric or #GEJCancer. A weaker signal for efficacy was reported with longer follow-up. Find out more in the #ESMODailyReporter 📌 https://ow.ly/hyRt50Xf02G #GICancer #TargetedTherapy

Concomitant publications at #ESMO25: highlighting the strength of global collaboration, ensuring that new data moves swiftly from the podium to the page, reaching the #OncologyCommunity worldwide through both presentation and publication.

From an idea that started during my ESMO - European Society for Medical Oncology ESMO/International Cancer Foundation (ICF) fellowship under the mentorship of Teresa Amaral MD, PhD to a poster presentation at ESMO 2025. Grateful for the chance to share our data from EuMelaReg which included almost 8000 melanoma patients, and be a part of such an amazing congress . #myESMOStory #ESMO2025 #oncology #melanoma

#ESMO25: Positive change may be on the horizon for #UvealMelanoma. Roger Bagge Olofsson discusses how novel strategies are offering the possibility of extended patient survival and may be practice-changing for both metastatic and primary disease. Combinations of #personalised treatments will be guided by factors such as HLA status, PRAME expression, tumour genetics and disease distribution, while a shift towards greater use of systemic therapy is anticipated for primary disease, enabling a reduction in vision-sacrificing interventions. Read his Opinion piece in the #ESMODailyReporter➡️ https://ow.ly/zO4z50XeZy7 #Immunotherapy #ImmunoOncology #PrecisionOncology

Use of #ctDNA as a decision-making aid to guide adjuvant chemotherapy may not be ready for prime time in #ColonCancer as two #ClinicalTrials fail to meet their primary endpoints. In an analysis of the DYNAMIC-III trial presented at #ESMO25, non-inferiority of 3-year recurrence-free survival was not confirmed between ctDNA-guided treatment and standard adjuvant chemotherapy in ctDNA-negative patients. The PEGASUS trial also failed to meet its primary endpoint, due in part to reduced power, with 12% false-negative cases occurring in ctDNA-negative patients at 2 years. Further investigations may help to determine the reasons behind these disappointing findings, which also reinforce the need to improve the sensitivity of ctDNA testing before it enters the clinic. Learn more in the #ESMODailyReporter ➡️https://ow.ly/uAeU50XeZ8h Dominik Modest #LiquidBiopsy #PrecisionOncology

#ESMO25: In the phase III IMvigor011 #ClinicalTrial, significantly prolonged disease-free survival was reported with atezolizumab versus placebo in #ctDNA-positive muscle-invasive #BladderCancer following radical cystectomy, providing the first trial evidence in support of minimal residual disease-guided adjuvant #immunotherapy in this setting. Find out more in the #ESMODailyReporter📌https://ow.ly/ZCCU50XeYU3 Alex Wyatt  #MIBC #ImmunoOncology #PrecisionOncology #LiquidBiopsy

🎉 We are delighted to announce that this year’s ESMO Research Fellowships have been awarded. #ESMO25 The ESMO Research Fellowship programme empowers early-career oncologists by offering opportunities to engage in high-quality research projects in both translational and clinical settings. It also provides international experience and fosters #collaboration with institutions of excellence. 🧪🌍 👏 Congratulations to the selected #YoungOncologists who will embark on this exciting next step in their #ProfessionalJourney.

👏We are pleased to announce Laura Marandino as the 2025 recipient of the ESMO José Baselga Fellowship for Clinician Scientists. ESMO recognises the crucial role of #ClinicianScientists in #TranslationalResearch in #oncology and #CancerCare. This Fellowship, supported by AZ, provides support to #CareerDevelopment, enabling #ProtectedTime for research, along with adequate resources and #mentorship. #ESMO25 Samra Turajlić; The Francis Crick Institute; The Royal Marsden NHS Foundation Trust